Sfoglia per Autore
Topoisomerase II alpha and TLE3 as predictive markers of response to anthracycline and taxane-containing regimens for neoadjuvant chemotherapy in breast cancer.
2014 Susini T; Berti B; Carriero C; Tavella K; Nori J; Vanzi E; Molino C; Di Tommaso M; Santini M; Saladino V; Bianchi S
Stable disease in a patient with metastatic leiomyosarcoma treated with trabectedin
2017 Tavella, K; Villanucci, A; Vannini, L; Lavacchi, D; Montelatici, S; Amunni, G; Mazzei, T
Retrospective analysis of 77 patients with ovarian cancer undergoing genetic testing for BRCA1 and BRCA2 mutations
2017 Tavella, K; Villanucci, A; Vannini, L; Rossi, V; Fantechi, B; Capone, G; Putignano, A L; Gensini, F; Porfirio, B; Amunni, G; Mazzei, T; Mini, E; Papi, L
Trabectedin in combination with pegylated liposomal doxorubicin in patients with ovarian tumors
2018 Villanucci A, Tavella K, Vannini L, Rossi V, Nobili S, Amunni G, Mazzei T, Mini E
Expression of FGD3 gene as prognostic factor in young breast cancer patients
2019 Renda, Irene; Bianchi, Simonetta; Vezzosi, Vania; Nori, Jacopo; Vanzi, Ermanno; Tavella, Ketty; Susini, Tommaso
Evolution of Adjuvant Chemotherapy for Breast Cancer: Review of Our Experience with Three Chemotherapy Regimens and Trastuzumab, Between 2000 and 2017
2019 Tommaso Susini, Arianna Vallario, Ketty Tavella, Alessandro Villanucci, Jacopo Nori
Long Term Results after Neoadjuvant Chemotherapy for Breast Cancer: A Single-center Experience
2020 Milo Giani, Arianna Vallario, Ketty Tavella, Alessandro Villanucci, Jacopo Nori, Ermanno Vanzi, Simonetta Bianchi, Tommaso Susini
Prognostic Role of Tumor Size Reduction >50% after Neoadjuvant Chemotherapy for Breast Cancer
2022 Giani, Milo; Tavella, Ketty; Renda, Irene; Tartarotti, Enrico; Nori, Jacopo; Vanzi, Ermanno; Bianchi, Simonetta; Susini, Tommaso
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Topoisomerase II alpha and TLE3 as predictive markers of response to anthracycline and taxane-containing regimens for neoadjuvant chemotherapy in breast cancer. | 2014 | Susini T; Berti B; Carriero C; Tavella K; Nori J; Vanzi E; Molino C; Di Tommaso M; Santini M; Saladino V; Bianchi S | |
| Stable disease in a patient with metastatic leiomyosarcoma treated with trabectedin | 2017 | Tavella, K; Villanucci, A; Vannini, L; Lavacchi, D; Montelatici, S; Amunni, G; Mazzei, T | |
| Retrospective analysis of 77 patients with ovarian cancer undergoing genetic testing for BRCA1 and BRCA2 mutations | 2017 | Tavella, K; Villanucci, A; Vannini, L; Rossi, V; Fantechi, B; Capone, G; Putignano, A L; Gensini, F; Porfirio, B; Amunni, G; Mazzei, T; Mini, E; Papi, L | |
| Trabectedin in combination with pegylated liposomal doxorubicin in patients with ovarian tumors | 2018 | Villanucci A, Tavella K, Vannini L, Rossi V, Nobili S, Amunni G, Mazzei T, Mini E | |
| Expression of FGD3 gene as prognostic factor in young breast cancer patients | 2019 | Renda, Irene; Bianchi, Simonetta; Vezzosi, Vania; Nori, Jacopo; Vanzi, Ermanno; Tavella, Ketty; Susini, Tommaso | |
| Evolution of Adjuvant Chemotherapy for Breast Cancer: Review of Our Experience with Three Chemotherapy Regimens and Trastuzumab, Between 2000 and 2017 | 2019 | Tommaso Susini, Arianna Vallario, Ketty Tavella, Alessandro Villanucci, Jacopo Nori | |
| Long Term Results after Neoadjuvant Chemotherapy for Breast Cancer: A Single-center Experience | 2020 | Milo Giani, Arianna Vallario, Ketty Tavella, Alessandro Villanucci, Jacopo Nori, Ermanno Vanzi, Simonetta Bianchi, Tommaso Susini | |
| Prognostic Role of Tumor Size Reduction >50% after Neoadjuvant Chemotherapy for Breast Cancer | 2022 | Giani, Milo; Tavella, Ketty; Renda, Irene; Tartarotti, Enrico; Nori, Jacopo; Vanzi, Ermanno; Bianchi, Simonetta; Susini, Tommaso |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile